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Purpose of the review: Alzheimer’s pathology is most likely universal in older individuals with 
Down syndrome (DS), due to having three copies of the amyloid precursor protein (APP) gene, 
resulting in amyloid-beta (Aβ) plaque deposition. They are an important population in which to 
consider clinical trials of treatments to prevent or delay the development of dementia. 
However, assessment of subtler cognitive changes is challenging due to the presence of 
intellectual disability.  
 
Recent findings: Recent research confirmed that older adults with DS often present with 
cognitive decline: more than 80% may experience dementia by age 65. Efforts have been made 
to improve and validate neuropsychological assessment and to describe the relationship with 
comorbidities such as epilepsy and haemorrhagic stroke. There have also been advances in 
biomarkers such as neuroimaging using amyloid positron emission tomography.  
 
Summary: Clinical trials of treatments, particularly in the presymptomatic phase of AD, are 
important to consider in individuals with DS given their high dementia burden, and may also 
serve as proof of concept for other forms of AD. However, further work is required to improve 
outcome measures and better understand the biomarkers of progression of pathology and 
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Key Points 
 The overall risk for Alzheimer’s disease individuals with Down syndrome (DS) has been 
estimated to be more than 80% by age 65; the mean age at dementia diagnosis was 
55.41 years. 
  
 PET imaging using amyloid-beat binding compounds have demonstrated significant 
amyloid binding in several brain regions in all individuals with DS by age 50.   
  
 Haemorrhagic strokes and epilepsy are both more common in individuals with DS and 
dementia than in controls, though intracerebral haemorrhage may be less common in 
DS than in those with duplication APP (the chromosome 21 gene implicated in AD in DS) 
suggesting the presence of protective factors in DS. 
  
 Several new test batteries for more detailed phenotyping of cognitive abilities in DS 
have been described, though further validation may be required for use as outcome 
measures in clinical trials. 
  
 Several randomised treatment trials in DS populations has been published, showing 
some potential for EGCG to improve cognitive abilities before the onset of dementia in 
DS (though further trials are required), while Vitamin E to reduce cognitive decline was 






























Following significant increases in life expectancy, 40% of individuals with Down syndrome (DS; 
trisomy of chromosome 21) in the UK are now aged 40 years and older (1) with similar 
increases reported in the USA (2). Alzheimer’s pathology is most likely universal in older 
individuals with DS, due to having three copies of the amyloid precursor protein (APP) gene, 
resulting in amyloid-beta (Aβ) deposition in plaques (3). DS is therefore an important 
population in which to consider clinical trials of treatments to prevent or delay the 
development of dementia due to Alzheimer's disease (AD). However, assessment of more 
subtle cognitive changes in adults with DS is challenging due to the presence of intellectual 
disability (ID). This review will consider recent research on cognitive decline and dementia in 
people with DS, including epidemiology, clinical and neuropsychological assessment, 
comorbidities and advances in biomarkers such as neuroimaging. 
 
Epidemiology 
There is a sharp increase in dementia prevalence in older adults with DS, from less than 10% by 
age 49, to more than 30% at 60 (3). As dementia is associated with high mortality rates, 
longitudinal data is required to estimate morbid risk. In a 14-year longitudinal study, the 
cumulative incidence for AD in women with DS was estimated to be more than 80% by age 65; 
the mean age at dementia diagnosis was 55.41 years (SD = 7.14) and median survival was 7 
years after diagnosis (4).  
 
Alexander et al. (5) compared age-specific incidence of previously recognised common 
cardiovascular, central nervous system, psychiatric, digestive and endocrine disorders in 6430 
individuals with DS (3009 females and 3421 males) and 19,176 general population controls 
(8966 females and 10,210 males) using the United Kingdom Clinical Practice Research Datalink 
(CPRD) in a matched retrospective cohort study. They found a median age of 47 years for 
dementia diagnosis, with dementia incidence more than 90 times higher (IRR 92.1; 54.3-156.2; 
P < 0.001) than in controls.  
 
Clinical assessment 
Diagnosing dementia in DS can be difficult, due to factors including variability of baseline 
cognitive level, heterogeneous presentation and lack of robust diagnostic tools.  Sheehan et al. 
(6) used clinical data from memory assessments of 85 people with DS, of whom 64 (73.5%) had 
an established diagnosis of dementia. Expert raters judged the cases as dementia or no 
dementia using their own clinical judgment and criteria from the International Classification of 
Disease (7) and Diagnostic Statistical Manual of Mental Disorders-IV-text revision (8). Clinicians’ 
judgement was most accurate in identifying previously diagnosed cases (84.4%), compared to 
70.3% with ICD-10 criteria and 56.3% with DSM-IV-TR criteria. Over time, the proportion of 
cases meeting international criteria increased.  The DSM-IV has recently been replaced by the 
DSM-5, which introduced a new term for dementia (major neurocognitive disorder) as well as a 
new diagnostic category for mild neurocognitive disorder, which may help to make earlier 
diagnoses in DS, though the validity of this diagnosis in the context of ID needs to be 
established (9). 
 
Tsao et al. (10) used a cross-sectional study of 120 adults with DS without dementia aged 20 to 
69 years, to examine the ‘normal’ ageing process. They found age-related deterioration in both 




Co-morbidities are common in DS, with well-established links between DS and congenital heart 
disease, epilepsy, hypothyroidism, visual and hearing impairments and depression (5,11). The 
prevalence of most of these conditions does not change significantly in the presence of 
dementia (4), requiring clinicians to remain observant for their emergence irrespective of 
cognitive decline.  
 
Alexander et al. (5) found incidence of epilepsy was elevated at all ages in DS, with a relative 
peak in adults 30 years and older (overall Incidence Relative Risk [IRR] 8.5; 7.3-9.8; p < 0.001 
and for age 30 years and older IRR 15.2). Epilepsy was significantly more common in DS where 
there was already a dementia diagnosis and occurred in more than 70% in a group with 
dementia (4).  Epilepsy diagnosis was also a significant predictor of mortality (p = 0.002), with 
those with an epilepsy diagnosis being 6.39 (2.02, 20.19) times more likely to die than those 
without.  
 
Sobey et al. (12) used population-level data to examine incident cardiovascular events in 4081 
people with DS versus 16,324 age-matched controls. Haemorrhagic strokes were more 
common in people with DS than non-DS controls (risk ratio [RR] = 3.31, 95% confidence interval 
[CI] 1.95, 5.60), as were ischaemic strokes (RR = 3.76, 95% CI 2.39, 5.92). Increased risk for 
ischaemic (but not haemorrhagic) stroke was substantially attenuated on adjustment for 
cardiovascular risk factors. Haemorrhagic stroke is most likely to be due to cerebral amyloid 
angiopathy (CAA) which results from the deposition of amyloid-β within the walls of cerebral 
blood vessels, which can eventually lead to intracerebral haemorrhage. Buss et al. (13) 
reviewed epidemiological and neuropathological studies comparing a rare form of familial AD 
caused by a duplication of the APP region on chromosome 21, with DS (three copies of 
chromosome 21). People with a familial duplication of APP appeared to have a higher 
frequency of intracerebral haemorrhage and possibly more extensive underlying vascular 
pathology. The authors concluded that Trisomy 21 may provide partial protection against the 
pro-haemorrhagic effects of APP duplication, and mechanisms related to amyloid-β processing 
and clearance that may be responsible for differences in amyloid angiopathy require further 
examination. DS represents a unique opportunity to study the cerebrovascular features of 
aging and AD in the context of protection against atherosclerosis and lower blood pressure but 
with significant CAA (14). 
 
Neuropsychology 
Floor effects are a particular concern when requiring tools that are sufficiently sensitive for 
tracking decline. Several widely used tests have recently been shown to be unsuitable for those 
with more severe ID or dementia, highlighting the need to develop more sophisticated 
neuropsychological tools for this population. However, object memory, semantic verbal 
fluency, the cued recall task, Tower of London, the CANTAB paired associate learning and 
simple reaction time tasks and the car and motorbike tracks of the NEPSY visuo-motor 
precision task have been highlighted as suitable for discriminating between those with and 
without dementia and tracking dementia related decline (15–19). The Raven’s Coloured 
Progressive Matrices (20) also appear to show deterioration from age 40 onwards in dementia-
free adults with DS (10). A closer look at the cued recall task originally described by Hartle (21) 
found both free and total recall scores discriminate age and dementia status in those with DS 
(22), however ~35% of participants without dementia were excluded from the final sample for 
being unable to perform the task or cooperate, limiting the suitability of this test, particularly 
in those with lower functioning.  
 
Validation of the NIH toolbox Cognitive Battery for ID found Flanker inhibition/attention tasks, 
picture vocabulary, oral reading and picture sequence memory tasks were accessible to those 
with ID, whereas dimensional change card sort, pattern comparison and list sorting tasks 
showed large floor effects, limiting their suitability as trial outcome measures (23). However, 
this study focused on a young sample (mean DS age = 16), including individuals with Fragile X 
syndrome and idiopathic ID, thus the suitability of these tasks in older adults with DS remains 
unclear. The Rapid Assessment for Developmental Disabilities (RADD) battery (24) and the 
NeuroTrax Moderate to Severe Impairment Assessment Battery (25) have also been proposed 
as suitable tools for assessing cognitive function in those with DS, yet neither study reported 
full performance data. 
 
A novel informant questionnaire addressing executive function, memory and language skills in 
DS was found to have high internal consistency, test-retest reliability and interrater reliability  
(26). This questionnaire could reliably discriminate between those with and without dementia, 
but showed no significant effects of age or gender, suggesting it could be useful for tracking 
cognitive decline, particularly where individuals are unable to engage with standard cognitive 
assessments. 
 
Dementia symptoms and presymptomatic decline in Down syndrome   
An ongoing debate is whether AD presents differently in DS compared to older adults from the 
general population. Dick et al. (27) compared neuropsychological profiles of higher-functioning 
DS individuals with dementia to individuals from the general population with advanced AD, 
adjusting for sex and functional impairment. They found similarities, suggesting the underlying 
pathology in both cases may have comparable effects on cognitive profiles.  
 
Previous studies suggested that behavioural and psychological symptoms and executive 
dysfunction may precede memory impairment in DS dementia (28,29). A recent cross-sectional 
study, however, suggested immediate memory impairment is one of the earliest signs of 
dementia in people with DS (30). Further longitudinal research is necessary to clarify the 
sequence of early changes in DS and their relationship to biomarkers such as neuroimaging. 
 
It is important to remember that not all cases of cognitive decline in DS are the result of 
dementia. A rare phenomenon highlighted by recent research is that of childhood and 
adolescent “regression” or “disintegration”, characterised by a sudden loss of daily living skills 
and cognitive decline. Worley et al. (31) summarized a case-series of what they termed DS 
disintegrative disorder, with results suggestive of a possible link with autoimmune function. A 
case study by Jacobs et al. (32) of a young adult male with DS experiencing similar 
deterioration highlights the diagnostic and treatment challenges these individuals face. 
 
Neuroimaging and other biomarkers 
Neuroimaging is a potential tool for monitoring biomarkers associated with progression from 
prodromal to symptomatic dementia in DS. Recent neuroimaging studies have used positron 
emission tomography (PET) scans with amyloid-beta (Aβ) binding compounds to characterize 
amyloid deposition and its association with dementia onset and symptoms. Sabbagh et al. (33) 
used florbetapir PET imaging to assess mean standard uptake value ratios (SUVRs) as the 
primary outcome measure of fibrillar Aβ burden in individuals with DS, DS with dementia and 
age-matched control subjects without DS. Significant group differences in mean SUVRs were 
reported, with uptake higher in DS individuals compared to controls, and greater still in those 
with DS and dementia.  
 
Jennings et al. (34) also used florbetapir PET imaging with individuals with DS, demonstrating 
that binding was strongly correlated with age, but not significantly associated with cognitive 
decline. Annus et al. (35) used PET with Pittsburgh compound B (PiB; another Aβ binding 
compound) in adults with DS, finding PiB binding first in the striatum around age 40. By age 50, 
all had significant PiB binding in several brain regions. Age strongly predicted amyloid binding 
and PiB binding was also significantly associated with diagnostic status and history of cognitive 
decline. Taken together, these studies suggest amyloid-imaging techniques could be used to 
stage individuals with DS in the pre-symptomatic period according to amyloid positive status 
on scans, and to characterise and monitor changes associated with the progression of AD 
pathology longitudinally.  
 
Additional neuroimaging studies include the investigation of EEG biomarkers, with Salem et al. 
(36) reporting an association between cognitive decline and theta slowing. Proton magnetic 
resonance spectroscopy has also been used with the putative glial biomarker myoinositol, 
which highlighted the possible existence of an overall higher glial inflammatory component in 
DS individuals (independent of dementia status) compared to control subjects (37). 
 
Biomarkers associated with cognitive functioning and decline in Down syndrome  
Plasma and CSF Aβ levels are potential biomarkers for AD. In individuals with DS, worse 
performance in a semantic verbal fluency task, poorer communication skills and a higher 
Dementia Questionnaire for Persons with ID score were recently found to be associated with 
higher plasma Aβ42 concentrations (38). Other AD biomarkers, including those related to 
inflammation and oxidative stress, are also of interest. Individuals with DS may have a unique 
neuroinflammatory state even before the onset of dementia, with implications for therapeutic 
intervention (39). Serum NGAL levels (Neutrophil Gelatinase-Associated Lipocalin, a newly 
identified neuroinflammatory constituent in AD) were shown to be significantly increased in DS 
subjects compared to those without DS, and positively associated with Aβ42 and Aβ(n42) in DS 
individuals with dementia and with Aβ40 and Aβ(n40) in DS individuals without dementia (40). 
Declining plasma Aβ42 and increasing proNGF (another inflammatory molecule) levels 
correlated with cognitive decline (41), while urinary isoprostane 8,12-iso-iPF2alpha, a marker 
of oxidative stress, was associated with cognitive decline in a longitudinal study of DS (42). 
 
Treatment trials 
Existing treatments, particularly acetylcholine esterase inhibitors, may be beneficial in 
individuals with DS who have dementia, but conclusive evidence for efficacy is lacking (43). 
Epigallocatechin-3-gallate (EGCG), a natural substance extracted from green tea, has been 
shown to inhibit DYRK1A (a kinase involved in Tau phosphorylation and implicated in AD in DS, 
as the DYRK1A gene is situated on chromosome 21) (44). De la Torre et al. (45) subsequently 
conducted a phase-2 randomized placebo-controlled trial of EGCG in young adults with DS (n = 
84) in combination with cognitive training to improve cognitive functioning. After 12 months, 
those in the treatment arm had significantly higher scores in measures of visual recognition 
memory, inhibitory control and adaptive behaviour, though the improvements were modest 
and further trials are required to determine longer-term safety and outcomes.  
 
A randomized placebo-controlled trial of Vitamin E to slow the progression of cognitive 
deterioration and dementia in individuals with DS was recently reported (46). Adults with DS 
older than 50 years (n = 337) were randomly assigned to receive either 1,000 IU of vitamin E 
orally twice daily or identical placebo for 3 years. There was no difference between drug and 
placebo on primary outcome (a brief praxis test), dementia rates, or secondary outcomes, with 
a trend towards higher rates of adverse events in those treated with vitamin E.  
 
Cooper et al. (15) reported a small randomized placebo-controlled feasibility trial (n = 21) of 
simvastatin to prevent onset of dementia in older individuals with Down syndrome, using a 
memory for objects test as primary outcome. This test appeared to be sensitive to change, 
favouring the treatment, but the trial was too small to demonstrate benefit of the treatment.  
 
Conclusion 
Individuals with DS are a unique population for researching AD and developing clinical trials of 
drugs for primary prevention (to avoid amyloid overproduction and deposition) and secondary 
prevention (to avoid onset of dementia after amyloid deposition), due to the relatively 
predictable onset of dementia in these adults. Such trials may benefit individuals with DS given 
their high dementia burden and may also serve as proof of concept for other forms of AD, yet 
improvements in outcome measures and trial design are required (47). While recent research 
has improved our understanding of dementia in DS, further work is necessary to understand 
the progression of pathology and its relationship with the development of symptoms during 
the pre-symptomatic period of AD in DS. Prospective longitudinal studies offer great promise 
for our future understanding of AD in DS (18,48). 
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Key Papers to Highlight 
4 **McCarron et al. (2014) 
 Provides an estimate of the morbid risk/ cumulative incidence for dementia in older adults 
with Down syndrome – no other similar papers in last two years, so this is an important 
study to highlight 
  
*Liogier d’Ardhuy et al., (2015) 
 A 6-month observation study determining the effectiveness of several cognitive tools to use 
for future interventional clinical studies 
 
*Sinai et al., (2016)  
 This paper presents one of the first validations of the Arizona Cognitive Test Batteries in 
older individuals with DS, including those with dementia, highlighting tasks which work well 
and tasks which are unsuitable for measuring cognition in these adults 
 
*Startin et al., (2016) 
 This paper presents a novel informant questionnaire, the ‘CS-DS’, to assess cognitive 
abilities in individuals with DS at all levels of functioning, while also being able to distinguish 
between those who have and do not have a clinical diagnosis of dementia 
 
31 *Worley et al., (2015) 
 Paper is of special interest because it describes several cases of ‘Down syndrome 
disintegrative disorder’ i.e. regression/decline in children and adolescents with DS 
 
33-35 **Sabbagh et al., (2015), Jennings et al., (2015) and Annus et al., (2016)  
 Three important studies that have successfully conducted PET imaging studies in adults 
with Down syndrome to look at β-amyloid deposition in vivo 
 
45 *de la Torre et al., (2016) 
 A paper reporting a randomised clinical trial of EGCG in younger individuals with Down 
syndrome, with some evidence for an effect 
  
46 **Sano et al., (2016) 
 A randomised trial of vitamin E (as anti-oxidant) in older individuals with Down syndrome, 
demonstrating lack of efficacy 
 
